Istradefylline (KW-6002)

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Parkinson's Disease

Conditions

Parkinson's Disease

Trial Timeline

Nov 1, 2004 → Nov 1, 2005

NCT ID

NCT00199394

About Istradefylline (KW-6002)

Istradefylline (KW-6002) is a phase 3 stage product being developed by Kyowa Kirin for Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00199394. Target conditions include Parkinson's Disease.

What happened to similar drugs?

20 of 20 similar drugs in Parkinson's Disease were approved

Approved (20) Terminated (3) Active (0)

✅Lemborexant + placeboEisaiApproved

✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved

✅Carbidopa/levodopa/entacaponeNovartisApproved

✅Carbidopa/levodopa/entacapone + Immediate release carbidopa/levodopaNovartisApproved

✅carbidopa/levodopa + Carbidopa/Levodopa/EntacaponeNovartisApproved

✅carbidopa, levodopa, entacaponeNovartisApproved

✅Levodopa/carbidopa/entacapone + Levodopa/carbidopaNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00250393	Phase 2	Completed	Nov 1, 2005	Oct 1, 2006	Parkinson's Disease
NCT00199446	Phase 2	Completed	Jul 1, 2005	Oct 1, 2006	Sleep Disorder
NCT00199433	Phase 2	Completed	May 1, 2005	Aug 1, 2006	Parkinson's Disease
NCT00199355	Phase 2	Completed	Apr 1, 2005	Mar 1, 2006	Parkinson's Disease
NCT00199394	Phase 3	Completed	Nov 1, 2004	Nov 1, 2005	Parkinson's Disease
NCT00199420	Phase 3	Completed	Jul 1, 2004	Dec 1, 2005	Parkinson's Disease
NCT00199407	Phase 3	Completed	Jun 1, 2004	Jan 1, 2006	Parkinson's Disease
NCT00456794	Phase 2	Completed	Mar 1, 2002	Oct 1, 2003	Parkinson's Disease

Competing Products

20 competing products in Parkinson's Disease

See all competitors

Product	Company	Stage	Hype Score
UB-312 + Placebo	Vaxxinity	Phase 1	19
NAV5001 + DaTscan	Navidea Biopharmaceuticals	Phase 3	22
piclozotan + 0.9% sodium chloride (normal saline)	Daiichi Sankyo	Phase 2	35
E2007	Eisai	Phase 3	32
ARICEPT	Eisai	Phase 3	40
Perampanel	Eisai	Phase 3	32
GPI 1485	Eisai	Phase 2	35
E2007	Eisai	Phase 3	40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo	Eisai	Phase 3	40
perampanel + placebo	Eisai	Phase 2	27
Lemborexant + placebo	Eisai	Approved	50
Placebo + E2007 + E2007	Eisai	Phase 3	32
E2007 + E2007 + E2007	Eisai	Phase 2	35
E2007	Eisai	Phase 2	35
E2007	Eisai	Phase 2	27
E2007	Eisai	Phase 2	27
2 mg perampanel + 4 mg perampanel + placebo comparator	Eisai	Phase 3	40
Istradefylline (KW-6002)	Kyowa Kirin	Phase 2	35
Istradefylline 20 mg or 40 mg	Kyowa Kirin	Phase 3	40
Perampanel	Eisai	Phase 2	27